-
公开(公告)号:US06531484B2
公开(公告)日:2003-03-11
申请号:US09974643
申请日:2001-10-10
申请人: Christopher A. Willoughby , Keith Rosauer , Kevin T. Chapman , Sander G. Mills , Dong-Ming Shen , Min Shu
发明人: Christopher A. Willoughby , Keith Rosauer , Kevin T. Chapman , Sander G. Mills , Dong-Ming Shen , Min Shu
IPC分类号: A61K3146
CPC分类号: C07D451/04 , A61K31/551 , A61K31/553 , A61K31/554 , A61K31/675 , C07D513/04
摘要: Pyrrolidine compounds of Formula I: (wherein R1, R2, R3, R4, R5, R6, R7, R8a, R8b, j, k, 1, m, and n are defined herein) are described. The compounds are modulators of CCR5 chemokine receptor activity. The compounds are useful, for example, in the prevention or treatment of infection by HIV and the treatment of AIDS, as compounds or pharmaceutically acceptable salts, or as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
摘要翻译: 描述式I的吡咯烷化合物(其中R1,R2,R3,R4,R5,R6,R7,R8a,R8b,j,k,1,m和n在本文中定义)。 这些化合物是CCR5趋化因子受体活性的调节剂。 所述化合物可用于例如预防或治疗HIV感染和治疗AIDS,作为化合物或药学上可接受的盐,或作为药物组合物中的成分,任选地与其它抗病毒剂,免疫调节剂,抗生素或疫苗组合。 还描述了治疗艾滋病的方法和预防或治疗HIV感染的方法。
-
公开(公告)号:US06265434B1
公开(公告)日:2001-07-24
申请号:US09543024
申请日:2000-04-04
申请人: Charles Caldwell , Kevin T. Chapman , Jeffrey Hale , Dooseop Kim , Christopher Lynch , Malcolm MacCoss , Sander G. Mills , Keith Rosauer , Christopher Willoughby , Scott Berk
发明人: Charles Caldwell , Kevin T. Chapman , Jeffrey Hale , Dooseop Kim , Christopher Lynch , Malcolm MacCoss , Sander G. Mills , Keith Rosauer , Christopher Willoughby , Scott Berk
IPC分类号: A61K3140
CPC分类号: C07D401/06 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D495/04
摘要: The present invention is directed to pyrrolidine compounds of the formula 1: (wherein R1, R2, R3, R4, R5, R6 and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-5 and/or CCR-3.
摘要翻译: 本发明涉及可用作趋化因子受体活性调节剂的式1的吡咯烷化合物(其中R 1,R 2,R 3,R 4,R 5,R 6和n如本文所定义)。 特别地,这些化合物可用作趋化因子受体CCR-5和/或CCR-3的调节剂。
-
公开(公告)号:US06593346B2
公开(公告)日:2003-07-15
申请号:US10075163
申请日:2002-02-14
申请人: Paul E. Finke , Kerry A. Hilfiker , Malcolm MacCoss , Kevin T. Chapman , Jennifer L. Loebach , Sander G. Mills , Ravi N. Guthikonda , Shrenik K. Shah , Dooseop Kim , Dong-Ming Shen , Bryan Oates
发明人: Paul E. Finke , Kerry A. Hilfiker , Malcolm MacCoss , Kevin T. Chapman , Jennifer L. Loebach , Sander G. Mills , Ravi N. Guthikonda , Shrenik K. Shah , Dooseop Kim , Dong-Ming Shen , Bryan Oates
IPC分类号: A61K31445
CPC分类号: C07D401/04 , C07D211/14 , C07D211/18 , C07D211/20 , C07D211/24 , C07D211/34 , C07D401/06 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/04 , C07D413/06 , C07D417/04 , C07D471/04 , Y02P20/582
摘要: The present invention is directed to compounds of the formula I: (wherein R1, R3, R4, R5, R6, R7, R8, X, n, x and y are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-5 and/or CCR-3.
-
公开(公告)号:US06358979B1
公开(公告)日:2002-03-19
申请号:US09590750
申请日:2000-06-08
申请人: Paul E. Finke , Kerry A. Hilfiker , Malcolm MacCoss , Kevin T. Chapman , Jennifer L. Loebach , Sander G. Mills , Ravi N. Guthikonda , Shrenik K. Shah , Dooseop Kim , Dong-Ming Shen , Bryan Oates
发明人: Paul E. Finke , Kerry A. Hilfiker , Malcolm MacCoss , Kevin T. Chapman , Jennifer L. Loebach , Sander G. Mills , Ravi N. Guthikonda , Shrenik K. Shah , Dooseop Kim , Dong-Ming Shen , Bryan Oates
IPC分类号: A61K31445
CPC分类号: C07D401/04 , C07D211/14 , C07D211/18 , C07D211/20 , C07D211/24 , C07D211/34 , C07D401/06 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/04 , C07D413/06 , C07D417/04 , C07D471/04 , Y02P20/582
摘要: The present invention is directed to compounds of the formula I: (wherein R1, R3, R4, R5, R6, R7, R8, X, n, x and y are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-5 and/or CCR-3.
摘要翻译: 本发明涉及可用作趋化因子受体活性调节剂的式I化合物(其中R 1,R 3,R 4,R 5,R 6,R 7,R 8,X,n,x和y如本文所定义)。 特别地,这些化合物可用作趋化因子受体CCR-5和/或CCR-3的调节剂。
-
公开(公告)号:US06432981B1
公开(公告)日:2002-08-13
申请号:US09590484
申请日:2000-06-08
申请人: Paul E. Finke , Kerry A. Hilfiker , Jennifer L. Loebach , Malcolm Maccoss , Sander G. Mills , Dong-Ming Shen , Bryan Oates
发明人: Paul E. Finke , Kerry A. Hilfiker , Jennifer L. Loebach , Malcolm Maccoss , Sander G. Mills , Dong-Ming Shen , Bryan Oates
IPC分类号: A61K31445
CPC分类号: C07D401/04 , C07D211/14 , C07D211/18 , C07D211/24 , C07D211/34 , C07D401/06 , C07D401/12 , C07D413/06 , C07D417/04 , C07D471/04
摘要: The present invention is directed to compounds of the formula I: (wherein R1, R2, R3, R4, R5, R7, R8, X, n, x and y are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-5 and/or CCR-3.
摘要翻译: 本发明涉及可用作趋化因子受体活性调节剂的式I化合物(其中R 1,R 2,R 3,R 4,R 5,R 7,R 8,X,n,x和y如本文所定义)。 特别地,这些化合物可用作趋化因子受体CCR-5和/或CCR-3的调节剂。
-
6.
公开(公告)号:US06166037A
公开(公告)日:2000-12-26
申请号:US141227
申请日:1998-08-27
申请人: Richard J. Budhu , Edward Holson , Jeffrey J. Hale , Christopher Lynch , Malcolm Maccoss , Scott C. Berk , Sander G. Mills , Christopher A. Willoughby
发明人: Richard J. Budhu , Edward Holson , Jeffrey J. Hale , Christopher Lynch , Malcolm Maccoss , Scott C. Berk , Sander G. Mills , Christopher A. Willoughby
IPC分类号: C07D401/06 , C07D401/14 , C07D403/06 , C07D405/14 , C07D409/14 , C07D495/10 , A61K31/445
CPC分类号: C07D401/06 , C07D401/14 , C07D403/06 , C07D405/14 , C07D409/14 , C07D495/10
摘要: The present invention is directed to pyrrolidine and piperidine compounds of the formula I: ##STR1## (wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4a, R.sup.4b, R.sup.4c, R.sup.4d, R.sup.4e, R.sup.4f, R.sup.4g, R.sup.4h, m, n, x and y are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-1, CCR-2, CCR-2A, CCR-2B, CCR-3, CCR-4, CCR-5, CXCR-3, and/or CXCR-4.
摘要翻译: 本发明涉及式I的吡咯烷和哌啶化合物:其中R1,R2,R3,R4a,R4b,R4c,R4d,R4e,R4f,R4g,R4h,m,n,x和y定义如下) 其可用作趋化因子受体活性的调节剂。 特别地,这些化合物可用作趋化因子受体CCR-1,CCR-2,CCR-2A,CCR-2B,CCR-3,CCR-4,CCR-5,CXCR-3和/或CXCR- 4。
-
公开(公告)号:US06248755B1
公开(公告)日:2001-06-19
申请号:US09542617
申请日:2000-04-04
申请人: Kevin Chapman , Jeffrey Hale , Dooseop Kim , Christopher Lynch , Shrenik Shah , Kothandaraman Shankaran , Dong-Ming Shen , Christopher Willoughby , Malcolm MacCoss , Sander G. Mills , Jennifer L. Loebach , Ravindra N. Guthikonda
发明人: Kevin Chapman , Jeffrey Hale , Dooseop Kim , Christopher Lynch , Shrenik Shah , Kothandaraman Shankaran , Dong-Ming Shen , Christopher Willoughby , Malcolm MacCoss , Sander G. Mills , Jennifer L. Loebach , Ravindra N. Guthikonda
IPC分类号: A61K3150
CPC分类号: C07D401/06 , C07D401/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D513/04
摘要: The present invention is directed to pyrrolidine compounds of the formula I: (wherein R1, R2, R3, R4, R5, R6, R14 and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-5 and/or CCR-3.
摘要翻译: 本发明涉及可用作趋化因子受体活性调节剂的式I的吡咯烷化合物(其中R 1,R 2,R 3,R 4,R 5,R 6,R 14和n如本文所定义)。 特别地,这些化合物可用作趋化因子受体CCR-5和/或CCR-3的调节剂。
-
公开(公告)号:US06511994B2
公开(公告)日:2003-01-28
申请号:US09973920
申请日:2001-10-10
申请人: Ronald M. Kim , Jiang Chang , Kevin T. Chapman , Sander G. Mills
发明人: Ronald M. Kim , Jiang Chang , Kevin T. Chapman , Sander G. Mills
IPC分类号: A61K31445
CPC分类号: C07D401/04 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04
摘要: Compounds of Formula I: (wherein R1, R2, R3, R4, Q, and X are defined herein) are described. The compounds are modulators of CCR5 chemokine receptor activity. The compounds are useful, for example, in the prevention or treatment of infection by HIV and the treatment of AIDS, as compounds or pharmaceutically acceptable salts, or as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
摘要翻译: 描述式I化合物(其中R 1,R 2,R 3,R 4,Q和X在本文中定义)。 这些化合物是CCR5趋化因子受体活性的调节剂。 所述化合物可用于例如预防或治疗HIV感染和治疗AIDS,作为化合物或药学上可接受的盐,或作为药物组合物中的成分,任选地与其它抗病毒剂,免疫调节剂,抗生素或疫苗组合。 还描述了治疗艾滋病的方法和预防或治疗HIV感染的方法。
-
公开(公告)号:US06498161B1
公开(公告)日:2002-12-24
申请号:US09543019
申请日:2000-04-04
申请人: Charles G. Caldwell , Kevin T. Chapman , Jeffrey Hale , Dooseop Kim , Christopher Lynch , Malcolm MacCoss , Sander G. Mills , Christopher Willoughby , Scott Berk , Ronald M. Kim
发明人: Charles G. Caldwell , Kevin T. Chapman , Jeffrey Hale , Dooseop Kim , Christopher Lynch , Malcolm MacCoss , Sander G. Mills , Christopher Willoughby , Scott Berk , Ronald M. Kim
IPC分类号: A61K31165
CPC分类号: C07D401/14 , C07D401/06 , C07D409/14 , C07D413/14 , C07D417/14 , C07D491/10 , C07F9/59 , C07F9/65583
摘要: The present invention is directed to pyrrolidine compounds of the formula I: (wherein R1, R2, R3, R4, R5, R6 and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-5 and/or CCR-3.
摘要翻译: 本发明涉及可用作趋化因子受体活性的调节剂的式I的吡咯烷化合物(其中R 1,R 2,R 3,R 4,R 5,R 6和n如本文所定义)。 特别地,这些化合物可用作趋化因子受体CCR-5和/或CCR-3的调节剂。
-
公开(公告)号:US06500844B1
公开(公告)日:2002-12-31
申请号:US09590487
申请日:2000-06-08
IPC分类号: A61K31445
CPC分类号: C07D401/08 , C07D211/58 , C07D413/08
摘要: The present invention is directed to compounds of the formula I: (wherein R1, R2, R3, R7, R8, X, Y, Z, x and y are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-5 and/or CCR-3.
摘要翻译: 本发明涉及可用作趋化因子受体活性调节剂的式I化合物(其中R1,R2,R3,R7,R8,X,Y,Z,x和y如本文所定义)。 特别地,这些化合物可用作趋化因子受体CCR-5和/或CCR-3的调节剂。
-
-
-
-
-
-
-
-
-